Jagsonpal Pharmaceuticals, a well-established small-cap player in the pharmaceutical sector with a market capitalization of ₹1,904 crore, has revealed the record date for its first-ever stock split. This strategic move aims to improve stock liquidity and make the shares more accessible to a broader base of investors, further enhancing market participation.
Details of the Stock Split
- Current Face Value: ₹5 per share.
- New Face Value: ₹2 per share.
- Stock Split Ratio: 2:1 (each share will split into two).
- Record Date: January 8, 2025.
The announcement came after shareholder approval via a postal ballot on December 11, 2024, and subsequent ratification by the Board of Directors on December 17, 2024. The subdivision reflects the company’s long-term vision to attract new investors while increasing trading activity and liquidity in its stock.
Financial Performance
Jagsonpal Pharmaceuticals has demonstrated remarkable growth over recent quarters:
- Q2 FY25 Net Profit: ₹11.46 crore, reflecting a 53.41% increase from the same period last year.
- Q2 FY25 Revenue: ₹74.69 crore, up 29.15% from ₹57.83 crore in the corresponding quarter of the previous year.
This robust financial performance underscores the company’s ability to leverage operational efficiencies and respond effectively to growing demand for its pharmaceutical products.
About Jagsonpal Pharmaceuticals
Founded in 1972, Jagsonpal Pharmaceuticals has built a strong legacy in the Indian pharmaceutical industry. The company specializes in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs), offering a diverse portfolio to meet various healthcare needs. Over the years, it has maintained a reputation for innovation, quality, and customer trust.
Impact of the Stock Split
The 2:1 stock split is expected to significantly impact the company’s market dynamics. By lowering the price per share, the split will make Jagsonpal’s stock more affordable for retail investors, thereby expanding its investor base.
This corporate action does not alter the company’s overall market capitalization but is anticipated to boost liquidity, enhance trading volumes, and solidify its presence in the market.
Coupled with its impressive financial performance and a legacy of over five decades in the pharmaceutical industry, this move positions the company for continued success and greater investor interest.
With its strategic focus and consistent growth trajectory, Jagsonpal Pharmaceuticals is poised to achieve new heights in the thriving healthcare sector.
Disclaimer: This article is for informational purposes only and should not be considered as investment advice.
Leave a Reply